Marker Therapeutics (MRKR) Registration Filing summary

Company overview and business model

• Clinical-stage immuno-oncology company developing T cell-based immunotherapies for hematological malignancies and solid tumors, using multi-antigen recognizing (MAR) T cell technology licensed from Baylor College of Medicine.

• MAR-T cell therapies selectively expand natural tumor-specific T cells without genetic modification, targeting multiple tumor antigens to reduce immune escape and toxicity.

• Advancing autologous and off-the-shelf MAR-T products for lymphoma, pancreatic cancer, and other indications.

• Phase 1 APOLLO study in relapsed lymphoma patients showed 78% objective response rate and 44.4% complete response, with favorable safety profile.

• Incorporated in Delaware, principal offices in Houston, Texas.

Financial performance and metrics

• Private Placement in December 2024 raised approximately $16.1 million in gross proceeds before expenses, with additional potential proceeds of up to $20.1 million from warrant exercises.

• As of January 10, 2025, 10,707,295 shares of common stock outstanding; up to 18,985,990 shares post-offering if all warrants are exercised.

Use of proceeds and capital allocation

• No proceeds from resale of shares by selling stockholders; proceeds from warrant exercises, if any, will be used for general corporate purposes and working capital.

• Board of Directors retains broad discretion over use of any proceeds received from warrant exercises.